Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASF-1096 cream dose-confirmation study in cutaneous lupus erythematosus
2007-004635-29Phase 3Terminated
- Sponsor
- Astion Pharma
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of levalbuterol in cutaneous lupus erythematosus (CLE), discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), sponsored by Astion Pharma. Started Sep 2007; status: terminated.
02
Drugs
levalbuterol
03
Conditions
cutaneous lupus erythematosus (CLE)discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on 2007-004635-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004635-29.